Integrative Physiology |
From the Departments of Anesthesiology (S.H.N., Y.W., J.M.S.), Pharmacology and Toxicology (O.S.S.), and Obstetrics and Gynecology (C.Y., Y.-L.D.), University of Texas Medical Branch, Galveston, Tex.
Correspondence to Dr Sharon H. Nelson, Department of Anesthesiology, Route 0591, University of Texas Medical Branch, Galveston, TX 77555. E-mail snelson{at}utmb.edu
| Abstract |
|---|
|
|
|---|
Key Words: cyclic GMP bradykinin immunohistochemistry N
-nitro-L-arginine methyl ester Ca2+ nitric oxide synthase
| Introduction |
|---|
|
|
|---|
Considerable evidence indicates that NO plays a role in pregnancy-induced uterine vasodilation. We have previously reported that acetylcholine is more potent and efficacious in producing dilation of isolated uterine arteries from pregnant than from nonpregnant patients.6 7 The acetylcholine-induced relaxation was blocked by NO synthase (NOS) inhibitors and thus is apparently mediated by NO.6 7 Furthermore, pregnancy-induced increases in basal NO production have been found in the uterine vasculature of rats,8 9 guinea pigs,10 11 and sheep.3 12 13
NO is produced by NOS, of which 3 isoforms have been identified: endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS).14 The NOS isoforms share a common overall catalytic scheme for the oxidation of L-arginine to NO and L-citrulline but can be divided into 2 functional classes based on the dependence of Ca2+ for activity.14 The constitutive forms, eNOS and nNOS, require Ca2+ for activity, but the inducible isoform, iNOS, has a Ca2+-independent activity. Ca2+-independent activity for eNOS also has been reported.15 16 17 18
In the present study, we tested the hypothesis that the greater NO-mediated relaxation of the human uterine artery during pregnancy is associated with increases in the activity and protein expression of the constitutive eNOS. The specific objectives of the study were to determine (1) whether NOS activity is greater in uterine arteries from pregnant patients than in arteries from nonpregnant patients, (2) the extent to which the NOS activity is Ca2+ dependent, (3) whether the changes in NOS activity are associated with an increase in eNOS protein expression, (4) whether the enhanced NOS protein expression is located in the endothelium, the nerves, or the vascular smooth muscle cells, and (5) whether the changes in NOS activity and protein expression observed in pregnancy are associated with elevated levels of cGMP (ie, the secondary mediator for NO actions).
| Materials and Methods |
|---|
|
|
|---|
Tissue Dissection
Sections of the uterus that contained the ascending branch of
the uterine artery were placed in cold (2°C) Krebs-bicarbonate
solution equilibrated with 95% O2 and 5%
CO2 immediately after hysterectomy and before
being taken to the laboratory, where the arteries were dissected from
the surrounding tissue. In preliminary studies with the NP arteries,
there was no loss of NOS activity during the first 180 minutes after
hysterectomy if the tissues were kept in cold (2°C) Krebs
solution.
NOS Activity
Evaluation of the NOS activity in human uterine arteries was
made by measuring [3H]-arginine conversion to
[3H]-citrulline. The method for NOS activity
was a modified method of Magness et al3 and Conrad et
al.8 Within 90 minutes of surgical removal of the uterus,
the arteries were frozen in liquid nitrogen and stored at -70°C
until NOS activity was measured. The tissues were stored at this
temperature for no more than 2 weeks. The tissues were
homogenized with an Ultra-Turrax T25
homogenizer (IKA Works) in a 1:10 dilution of ice-cold
homogenizing buffer, which contains (in mmol/L)
sucrose 50, HEPES 25, DL-dithiothreitol 1, leupeptin 10,
pepstatin A 10, chymostatin 10, antipain 10, soybean trypsin
inhibitor 10, and phenylmethylsulfonyl fluoride
100.
The samples were centrifuged at 1000g for 15 minutes
at 4°C. Dowex (50W-X8 200-400 mesh; Bio-Rad) cation exchange resin
(200 mg) was added to 2 mL of the homogenate to eliminate
endogenous L-arginine. After
centrifugation, the supernatant (100 µL) was added to
incubation buffer (100 µL), which contained 20 mmol/L flavin
adenine dinucleotide, 4 µmol/L tetrahydrobiopterin,
20 U/mL calmodulin, 40 µmol/LL-arginine, 0.625 mCi/L
L-[3H]-arginine
(Amersham), 1 mmol/L NADPH, 50 mmol/L sucrose, 25 mmol/L
HEPES, and 1 mmol/L CaCl2. To determine the
degree of Ca2+ dependence of this NOS activity,
Ca2+ was omitted and 2 mmol/L EGTA was added
to chelate any remaining Ca2+. After a 30-minute
incubation period at 25°C, 1.3 mL of "stop buffer" (80
mmol/L HEPES, 8 mmol/L EDTA) was added. The
[3H]-citrulline produced by the enzyme reaction
was separated from [3H]-arginine by the
addition of 1 mL of Dowex (50W-X8 200-400 mesh) and water mixture (1:1)
and subsequently centrifuged at 200g for 15 minutes.
Supernatant (0.5 mL) was removed, mixed with 4.5 mL of scintillation
fluid, and counted on a Beckman LS 3801 scintillation counter. The
values of samples heated at 65°C for 30 minutes to
inactivate enzymes were subtracted from total counts to
reflect apparent NOS activity. The NOS inhibitors
N
-nitro-L-arginine
methyl ester (L-NAME) and nitroarginine were added to aliquots of
homogenate to inhibit the conversion of
L-arginine to L-citrulline.
The amount of arginine metabolites reduced by the NOS
inhibitors reflects the NOS activity (NO and citrulline
production). The protein concentration was determined according
to the Bradford method. The NOS activity was expressed in picomoles of
arginine metabolites produced per milligram of protein per minute.
Western Analysis
The method of Dong et al19 was used for the
analysis. Human uterine arteries (
100 mg) were
homogenized in 50 mmol Tris/L buffer (pH 7.4)
containing 0.1 mmol EGTA/L, 0.14 mL ß-mercaptoethanol/mL,
100 mmol phenylmethylsulfonyl fluoride/L, and 0.2 mg
trypsin inhibitor/mL and centrifuged. The pellet
(membranous fraction) was resuspended in buffer. The proteins in all
subcellular fractions were measured with the BCA kit (Pierce). Positive
control proteins were obtained from the membrane fractions of human
umbilical endothelial cells (eNOS) and the cytosolic
fractions of rat cerebellum (nNOS) and cytokine-stimulated RAW
264.7 cells (iNOS). The latter 2 positive controls were cross-reactive
with human tissue (Transduction Laboratories). In each blot, 1 lane was
loaded with protein from an appropriate positive control.
Equal amounts of protein were size fractionated on 7.5% (wt/vol) SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. The blots were then incubated with specific primary antibodies (monoclonal; Transduction Laboratories) for 1 hour at room temperature. The final dilutions were 1:1000 for nNOS, 1:1000 for iNOS, and 1:500 for eNOS (vol/vol) in the blocking buffer. After the blots were washed and incubated with horseradish peroxidaseconjugated goat anti-mouse immunoglobulin antibody, the membranes were washed and the enhanced chemiluminescence reagent (ECL kit; Amersham) was added and incubated for 1 minute at room temperature. The blots were exposed to autoradiographic film, and the intensity of specific immunoreaction bands was quantified through densitometric scanning. The data are expressed as densitometric units. Both the elimination of the primary antibody and the use of nonNOS-related monoclonal antibody indicated the specificity of the NOS protein bands at appropriate molecular sizes (data not shown).
Immunohistochemistry
Uterine arterial segments were fixed in 10%
formalin in phosphate buffer, embedded in paraffin, and cross-sectioned
at 6 µm. Sections from pregnant and nonpregnant patients were
immunostained at the same time and under similar conditions
so a direct comparison could be made among the groups. After
deparaffinization, sections were rehydrated in graded ethanol and then
incubated in 3% H2O2 in
absolute methanol for 10 minutes to quench endogenous
peroxidase activity. To eliminate nonspecific background, sections were
incubated in a nonimmune serum (normal goat serum). The localization of
eNOS, nNOS, and iNOS was attempted by using isoform-specific antibodies
(Alexis Biochemicals) and indirect immunoperoxidase detection via the
Labeled-[strept] Avidin-Biotin method (Histostain SP-Broad
Spectrum/AEC Kit; Zymed). Sections were incubated with eNOS (bovine
monoclonal antibody, 1:250), nNOS (rat monoclonal antibody, 1:1000), or
iNOS (rat macrophage monoclonal antibody, 1:500) for 1 hour in
a moist chamber at room temperature. All of the antibodies were
cross-reactive with the respective human NOS. Optimal concentrations of
the primary antibodies were determined based on preliminary studies.
For a negative control, the primary antibody was replaced with normal
mouse or rabbit IgG (Vector). Sections were then rinsed for 15 minutes
in 10 mmol/L PBS, incubated for 10 minutes at room temperature
with a biotinylated secondary antibody (Histostain SP Kit), washed in
PBS, and incubated for 10 minutes with a streptavidinhorseradish
peroxidase complex. Sections were washed in PBS and incubated in
substrate (hydrogen peroxidechromogen [amino-ethylcarbazol]
mixture). Sections were counterstained with hematoxylin and mounted.
The sections were examined by 4 investigators who were blinded to the
identity of the tissue. The presence of a brownish-red stain was
qualitatively assessed with a scale of 0 to 4 (no staining to heavy
staining) at 3 locations: endothelium, media, and
adventitia.
Basal Levels of cGMP Production
Duplicate uterine arterial segments (10 to 30 mg)
from pregnant and nonpregnant patients were incubated for 60 minutes in
an atmosphere of 95% O2 and 5%
CO2 in Krebs buffer at 37°C.
Endothelium was removed from some of the segments
before incubation. Segments were changed to tubes containing Krebs
solution (for basal levels) or Krebs solution with L-NAME (0.1
mmol/L) and incubated for 30 minutes or Krebs solution with
bradykinin (l µmol/L) added for the final 10 minutes. The
studies were not conducted in the presence of a phosphodiesterase
inhibitor such as 3-isobutyl-1-methylxanthine
because of the interest in determining the levels of cGMP that existed
during various experimental conditions in earlier studies on
pregnancy-induced changes in constrictor functions of the uterine
artery.6 7 At the end of the incubation period, segments
were quickly frozen in liquid nitrogen, immersed in ice-cold 1%
trichloroacetic acid, homogenized, and centrifuged.
The supernatant was frozen (-70°C) until assayed for cGMP with a
radioimmunoassay kit (cGMP [125I] assay system
with Amerlex-M magnetic separation; Amersham International). The
results are reported in femtomoles of cGMP per milligram protein.
Endothelium Removal
To evaluate the role of endothelium on
NO-mediated cGMP production in the vascular smooth muscle, the
endothelium was removed from randomly selected
arterial rings by gently rubbing the
endothelial layer with tungsten wire (0.38 mm) for
1 minute. Control arterial rings from the same patient were
studied in parallel. Confirmation of endothelium
removal by this method has been reported with
histological and physiological
studies on human uterine arteries.6
Statistical Analysis
Data were analyzed using the Mann-Whitney test or
Students t test, as appropriate. Data presented
are mean±SEM. Results were considered significant at the
P<0.05 level.
| Results |
|---|
|
|
|---|
L-NAME (0.4 mmol/L), in the presence of Ca2+
(Figure 1A
), decreased the
production of total arginine metabolites by 91.9±8.6% (n=7)
in paired P arteries and by 45.8±6.7% (n=7) in paired NP arteries
(P<0.01). Higher concentrations (1 and 4 mmol/L) of
L-NAME did not produce any greater inhibition of arginine metabolite
formation. Another NOS inhibitor, nitroarginine (0.4
mmol/L), inhibited the total arginine metabolite formation to a similar
extent as that of L-NAME in P arteries (n=3) and NP arteries (n=3). The
total NOS activity expressed as the difference between the amount of
arginine metabolites formed in the absence and presence of L-NAME was
11.7±1.8 (n=7) and 3.1±0.9 (n=7) pmol · mg
protein-1 · min-1
(P<0.01) in P and NP arteries, respectively. Thus, the
total NOS activity was 3 times greater in the P arteries than in the NP
arteries.
|
In Ca2+-free medium L-NAME (0.4 mmol/L)
decreased the formation of arginine metabolites by 84.0±6.9% (n=7) in
paired P arteries and by 36.3±5.0% (n=7) in paired NP arteries
(Figure 1B
). The NOS activity in a
Ca2+-free incubation medium, expressed as the
difference between the amount of arginine metabolites formed in the
absence and presence of L-NAME, was 5.9±0.5 (n=7) and 2.4±0.6 (n=7)
pmol · mg protein-1 ·
min-1 (P<0.01), respectively, in P
and NP arteries (Figure 1B
). The
Ca2+-independent NOS activity was significantly
greater (P<0.01) in the P arteries than in the NP arteries.
Furthermore, the Ca2+-dependent NOS activity,
expressed as the difference between the NOS activity in the presence
and absence of Ca2+, was significantly greater
(P<0.01) in the P arteries than in the NP arteries.
NOS Expression
Figure 2A
depicts
representative Western immunoblots of eNOS
protein expression in uterine arteries from 3 pregnant and 3
nonpregnant patients. A single band at 140 kDa was detectable with both
P and NP arteries and was similar in size to the band with human
umbilical vein endothelial cell protein standard. The
expression of eNOS protein was consistently greater in the P
than in the NP arteries. Densitometry of the bands shows that the eNOS
expression was 1.5 times greater (P<0.05) in the P arteries
(1.3±0.2 densitometric units, n=6) than in the NP arteries (0.8±0.1
densitometric unit, n=7).
|
In early experiments, the expression of nNOS was demonstrated in 3 of 5
P arteries and in 3 of 6 NP arteries. In subsequent studies, when care
was taken to prevent damage to the adventitia during dissection, nNOS
was demonstrated in all of the uterine arteries (1 P artery and 3 NP
arteries, Figure 2B
). Of the arteries that demonstrated nNOS
expression, there was no apparent difference in the relative units of
nNOS expression in the P arteries (1.2±0.4 densitometric units, n=4)
and NP arteries (1.9±0.7 densitometric, n=6).
No iNOS expression was detected in either the P or NP arteries. It should be noted that the human uterine artery appears to have the capacity for iNOS induction, because iNOS expression could be demonstrated when NP arteries (n=3) were exposed to 100 U interleukin-1B (results not shown).
NOS Localization
Sections of 5 P arteries and 7 NP arteries were examined for
isoform specific staining of NOS. Of the NP arteries, 4 patients were
in the follicular phase and 3 patients were in the luteal phase of the
menstrual cycle. In the P arteries, there was consistently
heavy staining of eNOS in the endothelium (Figure 3A
). In the NP arteries, the staining
varied from moderate in those from patients in the follicular phase
(Figure 3B
) to slight in those from patients in the luteal phase
(Figure 3C
). Thus, qualitatively, the staining of eNOS appeared
to be in the order of P arteries>NP (follicular) arteries>NP (luteal)
arteries. There was slight but detectable staining for nNOS in the
adventitia (Figure 4
, top and bottom),
but not the endothelium or smooth muscle (Figure 4
, top), of all of the arteries examined. In contrast to the
heavy staining for eNOS, the staining of nNOS appeared to be similar in
the P arteries (Figure 4A
) and NP arteries (Figure 4B
).
None of the arteries exhibited any detectable staining of iNOS in the
vascular smooth muscle or the endothelium. Also, there
was no positive staining in the negative control sections exposed to
mouse or rabbit IgG instead of the primary antibodies (results not
shown).
|
|
cGMP Levels
Basal levels of cGMP in uterine arteries with
endothelium were 1.7 times higher in the P arteries
than in the NP arteries (Table
). L-NAME (0.1
mmol/L) reduced the basal content of cGMP by 70.7±3.0% in the P
arteries (n=7) and by 22.7±5.2% in the NP arteries (n=7)
(P<0.01). After removal of the endothelium,
the basal content of cGMP was reduced by 43.2±5.0% in the P arteries
(n=5) (P<0.01) and by 27±6.9% in the NP arteries (n=6)
(P<0.05) (Table
). Bradykinin (1 µmol/L), a
receptor-dependent activator of eNOS, increased the levels
of cGMP by 118.5±16.5% in the P arteries (n=5) and by 68.0±8.3% in
the NP arteries (n=6) (P<0.05) (Table
). To determine
whether the incubation of the human uterine artery resulted in an
induction of iNOS, experiments with the NP arteries (n=8) were
conducted in the absence and presence of dexamethasone
(10 µmol/L), an inhibitor of induction of iNOS. The
results showed that the presence of dexamethasone did not
alter the basal cGMP levels (data not shown).
|
| Discussion |
|---|
|
|
|---|
The following results indicate that eNOS accounts for most of the
pregnancy-associated increase in NO production. First, the
Ca2+-dependent NOS activity, indicating
involvement of the constitutive isoforms of NOS (eNOS, nNOS), was
8
times greater in the P arteries than in the NP arteries. Second, the
protein expression of eNOS was greater in the P arteries than in the NP
arteries (Figure 2A
). Third, immunohistochemical staining with
eNOS-specific antibody revealed a qualitatively greater staining in the
endothelium of the P arteries than of the NP arteries
(Figure 3
). Fourth, bradykinin, known to increase cGMP levels by
releasing NO from the endothelium, produced a much
greater increase in cGMP levels in the P arteries than in the NP
arteries. Thus, it can be reasonably concluded that the
pregnancy-enhanced NOS activity in uterine arteries reflects mainly an
increased eNOS activity.
Both the P and NP arteries exhibited staining for nNOS. The staining
appeared to be located in nerve fibers mainly in the adventitia (Figure 4
). The presence of nNOS in the neuronal innervation is
consistent with our previously reported findings that the
response of the human uterine artery to periarterial nerve
stimulation contains a NO-mediated vasodilator component.6
Similarly, Morris20 reported that the uterine arteries of
guinea pigs exhibited a vasoconstrictor and a vasodilator response to
nerve stimulation. The vasodilator response was partially blocked by a
NOS inhibitor. On the other hand, Magness et
al13 did not find nNOS staining in the ovine uterine
artery.
Western analysis demonstrated nNOS expression in the P and NP
arteries. That nNOS protein expression was not greater in P arteries
suggests that the increase in the Ca2+-dependent
NOS activity (Figure 1A
) was due to eNOS, not nNOS. The protein
expression is in accord with the findings that the human uterine
arteries consistently exhibited both positive
immunostaining for nNOS (present study) and
NO-mediated neurogenic vasodilatation.6
The iNOS isoform of NOS in the P and NP arteries was not detectable by
Western analysis or immunohistological staining
with a monoclonal antibody for iNOS that is cross-reactive with human
tissue. Magness et al13 concluded that there also was
little or no iNOS activity in the ovine uterine artery. Their
conclusion was based in part on the finding that the NOS activity in
the ovine uterine artery was largely Ca2+
dependent. Interestingly, in the present study we found ample
Ca2+-independent NOS activity, especially in the
P arteries (Figure 1B
). However, the fact that there is
Ca2+-independent NOS activity despite the lack of
any detectable iNOS suggests the existence of a
Ca2+-independent mechanism for activation of the
constitutive isoforms of NOS in the human uterine artery. In support of
this suggestion, there is evidence that shows a
Ca2+-independent component in the signal
transduction pathway for activation of eNOS.15 16 17 18
In the present experiments, we expressed the NOS activity as the
difference between the amount of arginine metabolites produced in the
absence and presence of maximal inhibitory concentrations
of L-NAME. Surprisingly, the amount of other arginine metabolites (eg,
ornithine, arginosuccinate) that could possibly be produced in the
presence of the NOS inhibitors was consistently and
significantly greater in the NP arteries than in the P arteries (Figure 1
). We have no explanation for this finding.
As noted in Materials and Methods, many of the uterine arteries were obtained without having available a clear indication of the phase of the menstrual cycle at the time of surgery. However, such information was available for the arteries used in the staining experiments that qualitatively demonstrated greater staining for eNOS in the arteries obtained from patients in the follicular phase than from those in the luteal phase. Although these results are qualitative, they are included in light of the controversy regarding whether NOS is modulated by estrogen in normally cycling women. These results are consistent with previous studies that show an increased responsiveness to acetylcholine in uterine arteries removed from patients with high plasma levels of estrogen during the follicular phase of the menstrual cycle.21 Also, we previously reported that the acetylcholine-induced NO/cGMPdependent vasodilatation of the human uterine artery was greater in the follicular phase than in the luteal phase.22 These results are in agreement with a growing body of evidence that indicates a role for estrogen in the upregulation of NOS activity in the uterine vasculature.4 23 24
In summary, the present study demonstrates that pregnancy is associated with increased eNOS levels in the human uterine artery. In both the P and NP arteries, eNOS was primarily located in the endothelium and nNOS was detected mainly in the adventitia. No detectable iNOS was found in either the P or NP arteries. The Ca2+-dependent NOS activity was 8 times greater in the P arteries than in the NP arteries. Although most of this pregnancy-induced increase in activity was Ca2+ dependent, a significant portion was clearly independent of Ca2+. The NO-mediated basal and bradykinin-stimulated levels of cGMP were markedly greater in the P than the NP arteries. These results, together with our previously reported functional studies that show that pregnancy causes increased NO-dependent relaxation responses to acetylcholine or periarterial nerve stimulation, constitute strong evidence for a prominent role of NO in the maintenance of human uterine vasodilation during pregnancy.
| Acknowledgments |
|---|
Received May 31, 2000; accepted June 28, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Meziani, A. Tesse, S. Welsch, H. Kremer, M. Barthelmebs, R. Andriantsitohaina, F. Schneider, and A. Gairard Expression and Biological Activity of Parathyroid Hormone-Related Peptide in Pregnant Rat Uterine Artery: Any Role for 8-Iso-Prostaglandin F2{alpha}? Endocrinology, February 1, 2008; 149(2): 626 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Telezhkin, T. Goecks, A. D. Bonev, G. Osol, and N. I. Gokina Decreased function of voltage-gated potassium channels contributes to augmented myogenic tone of uterine arteries in late pregnancy Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H272 - H284. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-A. Scott, A. Tremblay, M. Brochu, and J. St-Louis Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3713 - H3719. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao, X. Huang, S. Yang, and L. Zhang Direct Effects of Nicotine on Contractility of the Uterine Artery in Pregnancy J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 180 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tesse, F. Meziani, E. David, N. Carusio, H. Kremer, F. Schneider, and R. Andriantsitohaina Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H520 - H525. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao, X. Huang, L. D. Longo, W. J. Pearce, and L. Zhang Regulation of baseline Ca2+ sensitivity in permeabilized uterine arteries: effect of pregnancy Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H413 - H420. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Guo, X. Lu, H. Ren, E. R. Levin, and G. S. Kassab Estrogen modulates the mechanical homeostasis of mouse arterial vessels through nitric oxide Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1788 - H1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. I. Gokina and T. Goecks Upregulation of endothelial cell Ca2+ signaling contributes to pregnancy-enhanced vasodilation of rat uteroplacental arteries Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2124 - H2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Nesbitt, R. J. Murphy, and K. P. O'Hagan Effect of gestational stage on uterine artery blood flow during exercise in rabbits J Appl Physiol, December 1, 2005; 99(6): 2159 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Vonnahme, M. E. Wilson, Y. Li, H. L. Rupnow, T. M. Phernetton, S. P. Ford, and R. R. Magness Circulating levels of nitric oxide and vascular endothelial growth factor throughout ovine pregnancy J. Physiol., May 15, 2005; 565(1): 101 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H.P. Hilgers, S. Bergaya, P. M.H. Schiffers, P. Meneton, C. M. Boulanger, D. Henrion, B. I. Levy, and J. G.R. De Mey Uterine Artery Structural and Functional Changes During Pregnancy in Tissue Kallikrein-Deficient Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1826 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.A. Kelly, B.C. Bond, and L. Poston Gestational profile of matrix metalloproteinases in rat uterine artery Mol. Hum. Reprod., June 1, 2003; 9(6): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Toda and T. Okamura The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Rosenfeld, C. Chen, T. Roy, and X.-T. Liu Estrogen Selectively Up-Regulates eNOS and nNOS in Reproductive Arteries By Transcriptional Mechanisms Reproductive Sciences, May 1, 2003; 10(4): 205 - 215. [Abstract] [PDF] |
||||
![]() |
S. Mateev, A. H. Sillau, R. Mouser, R. E. McCullough, M. M. White, D. A. Young, and L. G. Moore Chronic hypoxia opposes pregnancy-induced increase in uterine artery vasodilator response to flow Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H820 - H829. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Bird, L. Zhang, and R. R. Magness Possible mechanisms underlying pregnancy-induced changes in uterine artery endothelial function Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R245 - R258. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Murphy, J. N. Herrington, J. P. Granger, and R. A. Khalil Enhanced [Ca2+]i in renal arterial smooth muscle cells of pregnant rats with reduced uterine perfusion pressure Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H393 - H403. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Sullivan, A. D. Giulumian, D. M. Pollock, L. C. Fuchs, and J. S. Pollock Functional NOS 1 in the rat mesenteric arterial bed Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H658 - H663. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Khalil and J. P. Granger Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R29 - R45. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao, X. Huang, S. Bae, C. A. Ducsay, and L. Zhang Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H238 - H246. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Joyce, T. M. Phernetton, C. E. Shaw, M. L. Modrick, and R. R. Magness Endothelial vasodilator production by uterine and systemic arteries. IX. eNOS gradients in cycling and pregnant ewes Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H342 - H348. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Buhimschi, G. Hall, L. P. Thompson, and C. P. Weiner Pregnancy and estradiol decrease GTPase activity in the guinea pig uterine artery Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2168 - H2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
|